Talking Techniques | CAR-T and CAR-NK cell therapies

Cancer research Cell and tissue biology Drug discovery and development Immunology
Audio player for the podcast episode "Talking Techniques | CAR-T and CAR-NK cell therapies". Use keyboard controls to play, pause, and navigate through the audio content.

In this episode of Talking Techniques, Ritwika Biswas, Field Scientist at Sino Biological US Inc. (PA, USA), walks us through the chimeric antigen receptor (CAR) development process and how T and natural killer (NK) cells can be utilized to carry these modular synthetic molecules. Ritwika also addresses the safety and efficacy of these cell therapies as well as the ethical considerations around them.

Contents:

  • Introduction: 00:00–01:22
  • An introduction to CAR-T therapy: 01:22–04:03
  • What is CAR-NK therapy and how does it differ from CAR-T therapy? 04:03–05:57
  • How are CARs developed? 05:57–09:28
  • What are the advantages of CAR-T and CAR-NK therapies? 09:28–12:45
  • What are the disadvantages? 12:45–16:30
  • How can we improve the safety and efficacy of these cell therapies? 16:30–18:25
  • What are the ethical considerations? 18:25–22:06
  • Are there any other applications of CAR-T therapy besides cancer? 22:06–24:44
  • Summary and future perspectives: 24:44–27:35

 

This feature was supported by Sino Biological.

 

Submit to the F1000Research Cell & Molecular Biology Gateway

Take your cell and molecular biology research further with the F1000Research Gateway. Benefit from trusted publishing, open access, and transparent peer review to ensure your findings are shared responsibly and make a lasting impact. Share your discoveries with a global audience while maintaining full control over your work.

Submit your research today at F1000Research Cell & Molecular Biology Gateway.